Epstein Barr Virus VCA IgG ELISA Kit

Name: Epstein Barr Virus VCA IgG ELISA Kit
SKU: DEIA3379
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Cerebrospinal Fluid, Serum

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The Epstein Barr Virus VCA IgG ELISA Kit is for the detection of IgG antibodies to viral capsid antigen of Epstein-Barr virus in human serum and for estimation of the intrathecal antibody production.

Contents of Kit

1. ELISA 8-well break-away strips coated with specific antigen. 96 wells
2. Standard A : Negative control serum, ready to use. (The antibody concentration for each Standard (A-E) is mentioned in Quality control certificate (AU/mL Artificial units/mL)). 1.3 mL
3. Standard B, ready to use. 1.3 mL
4. Standard C, ready to use. 1.3 mL
5. Standard D : Calibrator, ready to use. 1.3 mL
6. Standard E : Positive control serum, ready to use. 1.3 mL
7. Anti-human IgG antibodies-Px conjugated: Px-conjugate, ready to use. 13 mL
8. Wash buffer concentrate (10×): 10× concentrated. 55 mL
9. Dilution buffer, ready to use. 60 mL
10. Chromogenic substrate (TMB substrate): ready to use. 13 mL
11. Stop solution: ready to use. 13 mL
Note: Control sera may be colorless to yellowish or blue due to the use of different diluents.

Storage

1. Store the kit and the reagents at 2 to 10°C, in a dry place and protected from the light. The date of expiration is indicated on the ELISA kit label and on labels of the components.
2. Store the unused strips in the provided plastic bag with the desiccant kept inside.
3. The ELISA kit should be used within three months after opening.
4. If you find damage at any kit component, please inform the manufacturer.

Precision

The intraassay variability (within the test) and the interassay variability (between tests) were determined by testing samples with different antibody concentrations. OD range: 0.322-2.852
Intraassay variation (n=number of parallels):

Interassay variation (n=number of repetitions of the testing):
The coefficient of interassay variability is max. 15%. It is measured for each particular Lot as comparison of the OD values of the same serum sample in several consecutive tests.

Detection Limit

The limit of detection was calculated as the minimal concentration that was at the 95% confidence level different from the Blank. The limit of detection was 1.6 AU/mL.

Sensitivity

The sensitivity was measured by testing the population sample that is expected to have anti-VCA IgG antibodies (blood donors, persons with active EBV infection). The results were confirmed by other commercial test. The sensitivity was 98.1%.

General Description

The Epstein Barr Virus VCA IgG ELISA Kit is intended for the detection procedures in EBV induced and EBV associated disease, such as infectious mononucleosis (IM) and the chronic active EBV infection. The test is also useful in the detection of Burkitt's lymphoma, nasopharyngeal carcinoma, carcinoma of the Waldeyer's ring and in characterization of opportunistic lymphoma (oligo- and polyclonal). The other use of the test is in characterization of chronic fatigue syndrome, in neuroinfections and immunosuppression which is frequently associated with EBV reactivation.

Citations

Have you cited DEIA3379 in a publication? Let us know and earn a reward for your research.

Background

Epstein-Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), is a pathogenic human virus classified under the γ-herpesviridae family. As a member of the herpesvirus family, the structure of EBV includes a double-stranded DNA genome of approximately 184 kb, encoding nearly 100 proteins. The virus is enveloped by a lipid and glycoprotein membrane, while its DNA is protected by a protein-based nucleocapsid. EBV is most well-known for causing infectious mononucleosis (glandular fever), but it is also associated with various benign and malignant diseases, including lymphoproliferative disorders, Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, and gastric cancer. Furthermore, recent studies have found a significant link between EBV and the development of multiple sclerosis, with a 32-fold increased risk of occurrence following EBV infection.

EBV is primarily transmitted through saliva, blood, and genital secretions. The virus enters host cells by binding specific glycoproteins to receptors on the cell surface. In epithelial cells, the viral glycoprotein BMRF-2 binds to β1 integrin, followed by endocytosis into the cytoplasm, where replication begins. For B cells, the viral glycoprotein gp350 binds to the CD21 receptor, leading to systemic infection. The EBV life cycle consists of lytic infection, latency, and reactivation stages. During the latent phase, the virus remains long-term in the host's B cells and can reactivate under certain conditions. This reactivation is typically asymptomatic but can cause serious health problems in immunocompromised patients.

Immune Evasion Mechanism of EBV (Silva JD, 2024) Figure 1. EBV-Mediated Immune Evasion Mechanism (Source: Silva JD, et al., 2024)

EBV infection is primarily diagnosed through serological tests, such as ELISA, EIA, and IFA, which can detect specific EBV antibodies like VCA-IgG, VCA-IgM, and EBNA-1 IgG. These tests help differentiate between acute and past infections. Currently, researchers are working on developing prophylactic vaccines against EBV, aiming to induce neutralizing antibodies and cell-mediated immune responses. Vaccine candidates, including viral glycoproteins like gp350, gH/gL, and gB, have shown promising immunogenic effects. Although vaccine development poses challenges, its potential in preventing and treating EBV-related diseases offers hope.

Alternative Names

EBV VCA IgG Test Kit
Epstein-Barr Virus VCA IgG Detection Kit
EBV VCA IgG Serology Kit

References